Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma
Jizhuang Wang, Fangqiong Hu, Yu Pei, Jun Wang, Zhuochao Liu, Qiyuan Bao, Weibin Zhang, Junxiang Wen
Topics & Concepts
DoxorubicinSorafenibIn vivoCancer researchCytotoxic T cellTumor microenvironmentDownregulation and upregulationOsteosarcomaFlow cytometryCD8MedicineImmune systemPharmacologyImmunologyBiologyIn vitroInternal medicineChemotherapyBiochemistryGeneBiotechnologyHepatocellular carcinomaCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesSarcoma Diagnosis and Treatment